Zobrazeno 1 - 10
of 198
pro vyhledávání: '"J. Leidner"'
Autor:
Cara B. Janusz, Tara C. Anderson, Andrew J. Leidner, Grace M. Lee, Kathleen Dooling, Lisa A. Prosser
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
The Advisory Committee on Immunization Practices (ACIP) recommends recombinant zoster vaccine (RZV) to prevent against herpes zoster (HZ) and related complications in immunocompetent adults ≥50 y and immunocompromised adults ≥19 y. In 2019, a sta
Externí odkaz:
https://doaj.org/article/60b984d5b82846baa32aac10192e5504
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 15, Iss 7, p e0009606 (2021)
An effective and widely used vaccine could reduce the burden of dengue virus (DENV) around the world. DENV is endemic in Puerto Rico, where the dengue vaccine CYD-TDV is currently under consideration as a control measure. CYD-TDV has demonstrated eff
Externí odkaz:
https://doaj.org/article/2e34002b38d04636b6e0121621a58d7c
Publikováno v:
Vaccine. 41:2914-2921
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::265ef1867b519d2cbcbd138ff0d1812f
https://doi.org/10.1016/j.vaccine.2023.03.045
https://doi.org/10.1016/j.vaccine.2023.03.045
Autor:
Andrew J, Leidner, Tara C, Anderson, Kai, Hong, Ismael R, Ortega-Sanchez, Angela, Guo, Jamison, Pike, Lisa A, Prosser, Kathleen L, Dooling
Publikováno v:
Value in Health. 26:204-215
This study aimed to estimate the cost-effectiveness of the use of recombinant zoster vaccine (RZV) (Shingrix), which protects against herpes zoster (HZ), among immunocompromised adults aged 19 to 49 years, as a contribution to deliberations of the Ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaffcf086acb8daf03b394da6d6c0985
https://doi.org/10.1016/j.jval.2022.08.003
https://doi.org/10.1016/j.jval.2022.08.003
Autor:
Tara C. Anderson, Nina B. Masters, Angela Guo, Leah Shepersky, Andrew J. Leidner, Grace M. Lee, Camille N. Kotton, Kathleen L. Dooling
Publikováno v:
American Journal of Transplantation. 22:986-990
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d89e23214755a21be317092bbf84818d
https://doi.org/10.1111/ajt.16649
https://doi.org/10.1111/ajt.16649
Autor:
Miwako Kobayashi, Jennifer L. Farrar, Ryan Gierke, Amadea Britton, Lana Childs, Andrew J. Leidner, Doug Campos-Outcalt, Rebecca L. Morgan, Sarah S. Long, H. Keipp Talbot, Katherine A. Poehling, Tamara Pilishvili
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 71:109-117
In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck SharpDohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e21e8dcf052e5f6f6e1697f02959bd
https://doi.org/10.15585/mmwr.mm7104a1
https://doi.org/10.15585/mmwr.mm7104a1
Autor:
Miwako, Kobayashi, Jennifer L, Farrar, Ryan, Gierke, Andrew J, Leidner, Doug, Campos-Outcalt, Rebecca L, Morgan, Sarah S, Long, Katherine A, Poehling, Adam L, Cohen, Sarah, Schillie
Publikováno v:
MMWR. Morbidity and mortality weekly report. 71(37)
The 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Merck SharpDohme LLC]) have been recommended for U.S. children,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e5f5771fedd93eafb14451bbfb1f06c
https://pubmed.ncbi.nlm.nih.gov/36107786
https://pubmed.ncbi.nlm.nih.gov/36107786
Publikováno v:
Lebensmittelchemie. 76
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de67aed09dd9ec8c6e02d844ac4c4b29
https://doi.org/10.1002/lemi.202259088
https://doi.org/10.1002/lemi.202259088
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Public Health. 44:e234-e240
Background Estimates in the research literature on the health-related quality of life (QOL) associated with pneumococcal disease exhibit variation. It complicates the selection of estimates in modeling projects that evaluate the health impact and eco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b1fc9c683d2d845f3aa5df9916abfad
https://doi.org/10.1093/pubmed/fdab159
https://doi.org/10.1093/pubmed/fdab159